| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net unrealized gains (losses) on marketable securities | 195 | -151 | ||
| Total other comprehensive income (loss) | 195 | -151 | ||
| Research and development | 68,989 | 62,203 | ||
| General and administrative | 14,366 | 13,379 | ||
| Total operating expenses | 83,355 | 75,582 | ||
| Loss from operations | -83,355 | -75,582 | ||
| Interest income | 3,887 | 2,373 | ||
| Interest expense | 1,459 | 314 | ||
| Other income (expense), net | -3 | -6 | ||
| Total other income, net | 2,425 | 2,053 | ||
| Net loss | -80,930 | -73,529 | ||
| Comprehensive loss | -80,735 | -73,680 | ||
| Net loss per common share, basic | - | -0.53 | ||
| Net loss per common share, diluted | - | -0.53 | ||
| Weighted average common shares outstanding, basic | - | 114,466,080 | ||
| Weighted average common shares outstanding, diluted | - | 114,466,080 | ||
| Net loss per common share, basic | -125.45 | - | ||
| Net loss per common share, diluted | -125.45 | - | ||
| Weighted average common shares outstanding, basic | 67,414 | - | ||
| Weighted average common shares outstanding, diluted | 67,414 | - | ||
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)